Basel, Switzerland-based KetoSwiss, a biotechnology company, announced that it has secured $4.8M (approximately €4.37M) in a Pre-Series A round of funding from various investors. The company didn’t disclose the identity of the investors.
KetoSwiss says it will use the funds to accelerate the development of its medical food for migraine and related neurological disorders.
What does KetoSwiss solve?
Migraine affects around 1B people worldwide, and while it is the most common neurological disorder, solutions targeting the root cause are lacking.
According to the company’s research, migraine is associated with metabolic impairment of the brain, and the company’s product MigraKet is a response to the special energy needs of a migraineur’s brain.
KetoSwiss: Developing brain fuels
Founded by Elena Gross (Founder and CEO), KetoSwiss specialises in developing innovative “brain fuels.”
These fuels come in two forms – nutraceuticals (supplements) and pharmaceuticals – specifically tailored to address migraine therapy under the name “MigraKet.”
The company claims that the remarkable aspect of the products lies in their efficacy as they target the root cause of migraines while avoiding any intolerable side effects.
At the heart of the Migraket is an endogenous metabolite – a ketone body. This unique substance serves as an alternative fuel for the brain, stepping in when the utilisation or transportation of glucose faces challenges.
The company claims to provide significant relief to migraine sufferers by employing this mechanism.
The Swiss company aims to broaden its treatment beyond migraine treatment, including other neurological disorders characterised by metabolic dysfunction, such as Alzheimer’s.
01
From port to startup fort: How Lars Crama is ‘Making it Happen’ in Rotterdam